866-997-4948(US-Canada Toll Free)

Hypertension Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 289 Pages


Global Markets Directs, \'Hypertension Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypertension. 

Hypertension Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hypertension.
  • A review of the Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hypertension pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hypertension.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Hypertension Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Hypertension 13
Hypertension Therapeutics under Development by Companies 15
Hypertension Therapeutics under Investigation by Universities/Institutes 21
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Hypertension Therapeutics Products under Development by Companies 27
Hypertension Therapeutics Products under Investigation by Universities/Institutes 34
Companies Involved in Hypertension Therapeutics Development 35
Bristol-Myers Squibb Company 35
Shionogi & Co., Ltd. 36
Sanofi-Aventis 37
AstraZeneca PLC 38
Daiichi Sankyo Company, Ltd 39
Merck & Co., Inc. 40
Dainippon Sumitomo Pharma Co., Ltd. 41
Takeda Pharmaceutical Company Limited 42
BioLineRx, Ltd. 43
Novartis AG 44
Samyang Corporation 45
Actelion Ltd 46
Axcan Pharma Inc. 47
Biocon Limited 48
Chong Kun Dang Pharmaceutical 49
Daewoong Pharmaceutical Co., Ltd. 50
Dong-A Pharmaceutical Co., Ltd. 51
Forest Laboratories, Inc. 52
Les Laboratoires Servier 53
Mitsubishi Tanabe Pharma Corporation 54
Nippon Shinyaku Co., Ltd. 55
Recordati S.p.A. 56
Bayer AG 57
IntelGenx Technologies Corp. 58
Medivir AB 59
NicOx SA 60
Compugen Ltd. 61
Palatin Technologies, Inc. 62
BTG International Ltd 63
Cytokinetics, Inc 64
Yuhan Corporation 65
XOMA Ltd. 66
Torrent Pharmaceuticals Limited 67
Choongwae Pharma Corp 68
Hanall Pharmaceutical Co., Ltd. 69
Ahn-Gook Pharmaceutical Co., Ltd. 70
LG Life Sciences, Ltd 71
Panacea Biotec Limited 72
DiaMedica Inc. 73
Proteo, Inc. 74
AFFiRiS AG 75
Respiratorius AB 76
Ache Laboratorios Farmaceuticos S/A 77
IMMD Inc. 78
AngioDesign 79
Mondobiotech Holding AG 80
PhaseBio Pharmaceuticals, Inc. 81
INNOPHARMAX, INC. 82
QUANTUM GENOMICS Corp. 83
Intercept Pharmaceuticals, Inc. 84
Cellceutix Corporation 85
Diakron Pharmaceuticals, Inc. 86
Biolink Group AS 87
Proreo Pharma AG 88
Bial - Portela & Ca, S.A. 89
BioAxone Therapeutic Inc. 90
Lee\'s Pharmaceutical Holdings Limited 91
Pharnext SAS 92
Sihuan Pharmaceutical Holdings Group Ltd. 93
MicroDose Therapeutx, Inc. 94
Shanghai Modern Pharmaceutical Co., Ltd. 95
Vicore Pharma AB 96
Kotobuki Pharmaceutical Co., Ltd. 97
Serodus AS 98
Hypertension Therapeutics Assessment 99
Assessment by Monotherapy Products 99
Assessment by Combination Products 100
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 106
azilsartan medoxomil - Drug Profile 106
riociguat - Drug Profile 108
riociguat - Drug Profile 110
Angiotensin Therapeutic Vaccine - Drug Profile 112
propranolol hydrochloride - Drug Profile 113
(AHU-377 + valsartan) - Drug Profile 114
OA2H - Drug Profile 116
PL-3994 - Drug Profile 117
QGC-001 - Drug Profile 119
BIA-5-1058 - Drug Profile 120
CGEN-856 - Drug Profile 121
CGEN-857 - Drug Profile 123
CK-2018509 - Drug Profile 124
CoVaccine HT - Drug Profile 125
(atorvastatin calcium + losartan potassium) - Drug Profile 127
(atorvastatin calcium + losartan potassium) - Drug Profile 128
DP-3005 - Drug Profile 129
MetPril - Drug Profile 130
SER-100 - Drug Profile 131
serelaxin - Drug Profile 133
IMD-1041 - Drug Profile 135
selexipag - Drug Profile 136
obeticholic acid - Drug Profile 138
CS-3150 - Drug Profile 141
KM-732 - Drug Profile 143
HPT-C/D-3G - Drug Profile 144
Renin Inhibitors - Drug Profile 145
MK-4618 - Drug Profile 146
rostafuroxin - Drug Profile 147
YH-16410 - Drug Profile 149
MK-8266 - Drug Profile 150
udenafil - Drug Profile 151
CK-2018571 - Drug Profile 153
BMS-823778 - Drug Profile 154
(irbesartan + trichlormethiazide) - Drug Profile 156
(irbesartan + trichlormethiazide) - Drug Profile 157
carvedilol - Drug Profile 158
doxazosin mesylate - Drug Profile 159
felodipine - Drug Profile 160
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 161
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 162
(levamlodipine + telmisartan) - Drug Profile 163
MK-5478 - Drug Profile 165
ACT-280778 - Drug Profile 167
(azilsartan medoxomil + chlorthalidone) - Drug Profile 168
(azilsartan medoxomil + chlorthalidone) - Drug Profile 169
AHU-377 - Drug Profile 170
(irbesartan + atorvastatin calcium) - Drug Profile 171
(candesartan + amlodipine besylate) - Drug Profile 172
ARBs + Statins - Drug Profile 173
Vaccine For Hypertension - Drug Profile 174
candesartan BA - Drug Profile 175
DasKloster-024701 - Drug Profile 176
DM-204 - Drug Profile 177
ramipril MR - Drug Profile 178
telmisartan - Drug Profile 179
candesartan cilexetil - Drug Profile 180
olmesartan - Drug Profile 181
S-05985 - Drug Profile 182
TAK-272 - Drug Profile 183
AZD-1722 - Drug Profile 184
MT-3995 - Drug Profile 186
MK-7145 - Drug Profile 187
AJH-801 + [cilnidipine] + [valsartan] - Drug Profile 188
AJH-801 + [cilnidipine] + [valsartan] - Drug Profile 189
Compound-21 - Drug Profile 190
(lercanidipine hydrochloride + enalapril maleate) - Drug Profile 192
Drug For Hypertension - Drug Profile 193
nebivolol + valsartan - Drug Profile 194
CK-2018488 - Drug Profile 195
(irbesartan + atorvastatin calcium) - Drug Profile 196
MP-157 - Drug Profile 198
Anti-Hypertensive Drug - Drug Profile 199
AGSAV-301 - Drug Profile 200
(olmesartan medoxomil + rosuvastatin calcium) - Drug Profile 201
Tylerdipine Hydrochloride - Drug Profile 202
(perindopril arginine + amlodipine besylate) - Drug Profile 203
KD-027 - Drug Profile 205
MK-8150 - Drug Profile 206
DSP-9599 - Drug Profile 207
Amlodipine + Dextromethorphan - Drug Profile 208
(azlisartan + amlodipine besilate) - Drug Profile 209
ZV Combi - Drug Profile 210
AGSAA-010 - Drug Profile 211
CWF-1001 - Drug Profile 212
ThermoStem Program - Drug Profile 213
nitric oxide - Drug Profile 214
FAD-286 - Drug Profile 216
Liquid Potassium Magnesium Citrate - Drug Profile 217
Renin Inhibitor - Drug Profile 218
pratosartan - Drug Profile 219
pratosartan - Drug Profile 220
AGNBS-002 - Drug Profile 221
AGNES-101 - Drug Profile 222
Nepolong - Drug Profile 223
Dual Action Receptor Antagonists - Drug Profile 224
PB-1046 - Drug Profile 225
AVE-3085 - Drug Profile 226
carvedilol CR - Drug Profile 227
(amiloride hydrochloride + spironolactone) - Drug Profile 228
(nifedipine + candesartan cilexetil) - Drug Profile 230
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 231
metoprolol succinate - Drug Profile 233
Drug For Pulmonary Hypertension-1 - Drug Profile 234
Drug For Pulmonary Hypertension-2 - Drug Profile 235
(rosuvastatin + amlodipine) - Drug Profile 236
Hypertension Therapeutics Drug Profile Updates 237
Hypertension Therapeutics Discontinued Products 261
Hypertension Therapeutics - Dormant Products 263
Hypertension Product Development Milestones 274
Featured News & Press Releases 274

Appendix 281
Methodology 281
Coverage 281
Secondary Research 281
Primary Research 281
Expert Panel Validation 281
Contact Us 282
Disclaimer 282

List of Table


Number of Products Under Development for Hypertension, H1 2013 20
Products under Development for Hypertension Comparative Analysis, H1 2013 21
Number of Products under Development by Companies, H1 2013 23
Number of Products under Development by Companies, H1 2013 (Contd..1) 24
Number of Products under Development by Companies, H1 2013 (Contd..2) 25
Number of Products under Development by Companies, H1 2013 (Contd..3) 26
Number of Products under Development by Companies, H1 2013 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2013 29
Comparative Analysis by Late Stage Development, H1 2013 30
Comparative Analysis by Mid Clinical Stage Development, H1 2013 31
Comparative Analysis by Early Clinical Stage Development, H1 2013 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 33
Products under Development by Companies, H1 2013 34
Products under Development by Companies, H1 2013 (Contd..1) 35
Products under Development by Companies, H1 2013 (Contd..2) 36
Products under Development by Companies, H1 2013 (Contd..3) 37
Products under Development by Companies, H1 2013 (Contd..4) 38
Products under Development by Companies, H1 2013 (Contd..5) 39
Products under Development by Companies, H1 2013 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2013 41
Bristol-Myers Squibb Company, H1 2013 42
Shionogi & Co., Ltd., H1 2013 43
Sanofi-Aventis, H1 2013 44
AstraZeneca PLC, H1 2013 45
Daiichi Sankyo Company, Ltd, H1 2013 46
Merck & Co., Inc., H1 2013 47
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 48
Takeda Pharmaceutical Company Limited, H1 2013 49
BioLineRx, Ltd., H1 2013 50
Novartis AG, H1 2013 51
Samyang Corporation, H1 2013 52
Actelion Ltd, H1 2013 53
Axcan Pharma Inc., H1 2013 54
Biocon Limited, H1 2013 55
Chong Kun Dang Pharmaceutical, H1 2013 56
Daewoong Pharmaceutical Co., Ltd., H1 2013 57
Dong-A Pharmaceutical Co., Ltd., H1 2013 58
Forest Laboratories, Inc., H1 2013 59
Les Laboratoires Servier, H1 2013 60
Mitsubishi Tanabe Pharma Corporation, H1 2013 61
Nippon Shinyaku Co., Ltd., H1 2013 62
Recordati S.p.A., H1 2013 63
Bayer AG, H1 2013 64
IntelGenx Technologies Corp., H1 2013 65
Medivir AB, H1 2013 66
NicOx SA, H1 2013 67
Compugen Ltd., H1 2013 68
Palatin Technologies, Inc., H1 2013 69
BTG International Ltd, H1 2013 70
Cytokinetics, Inc, H1 2013 71
Yuhan Corporation, H1 2013 72
XOMA Ltd., H1 2013 73
Torrent Pharmaceuticals Limited, H1 2013 74
Choongwae Pharma Corp, H1 2013 75
Hanall Pharmaceutical Co., Ltd., H1 2013 76
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 77
LG Life Sciences, Ltd, H1 2013 78
Panacea Biotec Limited, H1 2013 79
DiaMedica Inc., H1 2013 80
Proteo, Inc., H1 2013 81
AFFiRiS AG, H1 2013 82
Respiratorius AB, H1 2013 83
Ache Laboratorios Farmaceuticos S/A, H1 2013 84
IMMD Inc., H1 2013 85
AngioDesign, H1 2013 86
Mondobiotech Holding AG, H1 2013 87
PhaseBio Pharmaceuticals, Inc., H1 2013 88
INNOPHARMAX, INC., H1 2013 89
QUANTUM GENOMICS Corp., H1 2013 90
Intercept Pharmaceuticals, Inc., H1 2013 91
Cellceutix Corporation, H1 2013 92
Diakron Pharmaceuticals, Inc., H1 2013 93
Biolink Group AS, H1 2013 94
Proreo Pharma AG, H1 2013 95
Bial - Portela & Ca, S.A., H1 2013 96
BioAxone Therapeutic Inc., H1 2013 97
Lee\'s Pharmaceutical Holdings Limited, H1 2013 98
Pharnext SAS, H1 2013 99
Sihuan Pharmaceutical Holdings Group Ltd., H1 2013 100
MicroDose Therapeutx, Inc., H1 2013 101
Shanghai Modern Pharmaceutical Co., Ltd., H1 2013 102
Vicore Pharma AB, H1 2013 103
Kotobuki Pharmaceutical Co., Ltd., H1 2013 104
Serodus AS, H1 2013 105
Assessment by Monotherapy Products, H1 2013 106
Assessment by Combination Products, H1 2013 107
Assessment by Stage and Route of Administration, H1 2013 109
Assessment by Stage and Molecule Type, H1 2013 112
Hypertension Therapeutics Drug Profile Updates 244
Hypertension Therapeutics Discontinued Products 268
Hypertension Therapeutics Discontinued Products (Contd..1) 269
Hypertension Therapeutics Dormant Products 270
Hypertension Therapeutics Dormant Products (Contd..1) 271
Hypertension Therapeutics Dormant Products (Contd..2) 272
Hypertension Therapeutics Dormant Products (Contd..3) 273
Hypertension Therapeutics Dormant Products (Contd..4) 274
Hypertension Therapeutics Dormant Products (Contd..5) 275
Hypertension Therapeutics Dormant Products (Contd..6) 276
Hypertension Therapeutics Dormant Products (Contd..7) 277
Hypertension Therapeutics Dormant Products (Contd..8) 278
Hypertension Therapeutics Dormant Products (Contd..9) 279
Hypertension Therapeutics Dormant Products (Contd..10) 280

List of Chart


Number of Products under Development for Hypertension, H1 2013 20
Products under Development for Hypertension Comparative Analysis, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Investigation by Universities/Institutes, H1 2013 28
Late Stage Products, H1 2013 30
Mid Clinical Stage Products, H1 2013 31
Early Clinical Stage Products, H1 2013 32
Discovery and Pre-Clinical Stage Products, H1 2013 33
Assessment by Monotherapy Products, H1 2013 106
Assessment by Combination Products, H1 2013 107
Assessment by Route of Administration, H1 2013 108
Assessment by Stage and Route of Administration, H1 2013 109
Assessment by Molecule Type, H1 2013 110
Assessment by Stage and Molecule Type, H1 2013 111

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *